Prostate Cancer Diagnosis Based on the Segmentation and Analysis of NIR Images Obtained Using Two PSMA-1 Based PDT Conjugates PSMA-1-Pc413 and PSMA-1-IR700

Authors

  • Rachid Sammouda Department of Computer Sciences, King Saud University, Riyadh, KSA

Keywords:

Prostate cancer, near-infrared (NIR) images, molecular weight PSMA-targeting PDT agents.

Abstract

Prostate cancer is among the widespread men

References

. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. Journal of the National Cancer Institute 1999; 91(12):1017-24.

. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin;65(1):5-29.

. Jermal A, Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., et al. Cancer Statistics, 2006. CA Cancer J Clin 2006;56:106.

. Momma T, Hamblin MR, Wu HC, Hasan T. Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: local control and distant metastasis. Cancer research 1998;58(23):5425-31.

. Swanson GP, Riggs M, Hermans M. Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol 2007;25(2):110-4.

. Swanson GP, Lerner SP. Positive margins after radical prostatectomy: implications for failure and role of adjuvant treatment. Urol Oncol;31(5):531-41.

. Theiss M, Wirth MP, Manseck A, Frohmuller HG. Prognostic significance of capsular invasion and capsular penetration in patients with clinically localized prostate cancer undergoing radical prostatectomy. Prostate 1995;27(1):13-7.

. Wright JL, Dalkin BL, True LD, et al. Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality. The Journal of Urology 2010;183(6):2213-8.

. Box GN, Ahlering TE. Robotic radical prostatectomy: long-term outcomes. Current Opinion in Urology 2008;18(2):173-9.

. Walsh PC, Lepor H, Eggleston JC. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. The Prostate 1983;4(5):473-85.

. Van der Aa F, Joniau S, De Ridder D, Van Poppel H. Potency after unilateral nerve sparing surgery: a report on functional and oncological results of unilateral nerve sparing surgery. Prostate Cancer and Prostatic Diseases 2003;6(1):61-5.

. McClure TD, Margolis DJ, Reiter RE, et al. Use of MR imaging to determine preservation of the neurovascular bundles at robotic-assisted laparoscopic prostatectomy. Radiology 2012;262(3):874-83.

. Burnett AL, Aus G, Canby-Hagino ED, et al. Erectile function outcome reporting after clinically localized prostate cancer treatment. The Journal of Urology 2007;178(2):597-601.

. Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. The Journal of Urology 2004;172(6 Pt 1):2227-31.

. Penson DF, McLerran D, Feng Z, et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. The Journal of Urology 2005;173(5):1701-5.

. Saranchuk JW, Kattan MW, Elkin E, Touijer AK, Scardino PT, Eastham JA. Achieving optimal outcomes after radical prostatectomy. Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4146-51.

. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. The Journal of Urology 2007;177(6):2106-31.

. Neuman BP, Eifler JB, Castanares M, et al. Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer. Clin Cancer Res;21(4):771-80.

. Agostinis P, Berg K, Cengel KA, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin;61(4):250-81.

. Anand S, Ortel BJ, Pereira SP, Hasan T, Maytin EV. Biomodulatory approaches to photodynamic therapy for solid tumors. Cancer Lett;326(1):8-16.

. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst 1998; 90(12):889-905.

. Lovell JF, Liu TW, Chen J, Zheng G. Activatable photosensitizers for imaging and therapy. Chem Rev;110 (5):2839-57.

. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004;5(8):497-508.

. Juzeniene A, Peng Q, Moan J. Milestones in the development of photodynamic therapy and fluorescence diagnosis. Photochem Photobiol Sci 2007;6(12):1234-45.

. Casas A, Di Venosa G, Hasan T, Al B. Mechanisms of resistance to photodynamic therapy. Curr Med Chem;18(16):2486-515.

. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7(5B):927-35.

. Kawakami M, Okaneya T, Furihata K, Nishizawa O, Katsuyama T. Detection of prostate cancer cells circulating in peripheral blood by reverse transcription-PCR for hKLK2. Cancer Res 1997;57(19):4167-70.

. Wright GL, Jr., Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996;48(2):326-34.

. Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003;9(17):6357-62.

. Mitsiades CS, Lembessis P, Sourla A, Milathianakis C, Tsintavis A, Koutsilieris M. Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. Clin Exp Metastasis 2004;21(6):495-505.

. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5(10):2674-81.

. Foss CA, Mease RC, Fan H, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res 2005;11(11):4022-8.

. Chen Y, Dhara S, Banerjee SR, et al. A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun 2009;390(3):624-9.

. Banerjee SR, Foss CA, Castanares M, et al. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem 2008;51(15):4504-17.

. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23(21):4591-601.

. Wang X, Ma D, Olson WC, Heston WD. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Mol Cancer Ther;10(9):1728-39.

. Kuroda K, Liu H, Kim S, Guo M, Navarro V, Bander NH. Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity. Prostate;70(12):1286-94.

. Huang SS, Wang X, Zhang Y, Doke A, Difilippo FP, Heston WD. Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker. Prostate;74(7):702-13.

. Wang X, Huang SS, Heston WD, Guo H, Wang BC, Basilion JP. Development of targeted near-infrared imaging agents for prostate cancer. Mol Cancer Ther;13(11):2595-606.

. Miller JD, Baron ED, Scull H, et al. Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: the case experience with preclinical mechanistic and early clinical-translational studies. Toxicol Appl Pharmacol 2007; 224(3):290-9.

. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med;17(12):1685-91.

. Nakajima T, Sano K, Choyke PL, Kobayashi H. Improving the efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model. Theranostics;3(6):357-65.

. Watanabe R, Hanaoka H, Sato K, et al. Photoimmunotherapy targeting prostate-specific membrane antigen: are antibody fragments as effective as antibodies? J Nucl Med;56(1):140-4.

. Taatjes DJ, Sobel BE, Budd RC. Morphological and cytochemical determination of cell death by apoptosis. Histochem Cell Biol 2008;129(1):33-43.

. Zhen Ma1, Jo

. Rachid Sammouda, Mohammed Sammouda, and Jamel Abu Hassan

. Rachid Sammouda, Nuru Adgaba, Ameur Touir and Ahmed Al-Ghamdi,

. Hugosson J, Carlsson S, Aus G, et al. 2010. Mortality results from the G

. New Zealand, Ministry of Health, Citation: Prostate Cancer Taskforce. 2012. Diagnosis and Management of Prostate Cancer in New Zealand Men: Recommendations from the Prostate Cancer Taskforce. Wellington: Ministry of Health; Published in May 2013 by the Ministry of Health PO Box 5013, Wellington 6145, New Zealand ISBN 978-0-478-40264-3 (online) HP 5647. This document is available at www.health.govt.nz.

. Ali Tabesh*, Member, IEEE, Mikhail Teverovskiy, Ho-Yuen Pang, Vinay P. Kumar, David Verbel, Angeliki Kotsianti, and Olivier Saidi, "Multifeature Prostate Cancer Diagnosis and Gleason Grading of Histological Images", IEEE TRANSACTIONS ON MEDICAL IMAGING, VOL. 26, NO. 10, OCTOBER 2007.

. J. Diamond, N. Anderson, P. Bartels, R. Montironi, and P. Hamilton,

Downloads

Additional Files

Published

2016-02-11

How to Cite

Sammouda, R. (2016). Prostate Cancer Diagnosis Based on the Segmentation and Analysis of NIR Images Obtained Using Two PSMA-1 Based PDT Conjugates PSMA-1-Pc413 and PSMA-1-IR700. International Journal of Sciences: Basic and Applied Research (IJSBAR), 25(2), 218–232. Retrieved from https://gssrr.org/index.php/JournalOfBasicAndApplied/article/view/5206

Issue

Vol. 25 No. 2 (2016)

Section

Articles

License

Authors who submit papers with this journal agree to the following terms.